Fluidigm to acquire DVS Sciences for $207.5M


Fluidigm (FLDM) agrees to acquire DVS Sciences for $207.5M in cash and stock in a deal it says will enable it to offer a comprehensive portfolio of advanced technologies serving the growing single-cell genomics and proteomics markets.

FLDM says DVS is best known for its multi-parameter single-cell protein analysis systems, including the the CyTOF2 Mass Cytometer, which analyzes antibody/metal complexes using atomic mass spectrometry.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs